Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

Completed

• Conditions: Rheumatoid Arthritis; COVID

• Registration Number: NCT04393233
• Lead Sponsor: University Hospital, Brest

Brief Summary

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-22
• Study Start: 2020-04-23
• Study First Submitted QC: 2020-05-18
• Study First Posted: 2020-05-19
• Primary Completion: 2020-08-23
• Study Completion: 2020-08-23
• Last Update Submitted: 2024-08-08
• Last Update Posted: 2024-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Rheumatoid arthritis satisfying ACR/EULAR criteria
• Ongoing DMARD therapy

Exclusion Criteria

• Inhability to consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis	1 Day	Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Trial Locations

Locations (1)

CHRU de Brest; 🇫🇷 Brest, France